Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

ll transplant. 52nd ASH Annual Meeting and Exposition. 2010. Abstract #169. Available at http://ash.confex.com/ash/2010/webprogram/Paper34050.html. Accessed November 2010.
  • McBride NC, Cavenagh JD, Ward MC, et al. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma. Leuk Lymphoma. 2001Jun;42(1-2):89-98.
  • NCCN Clinical Practice Guidelines in Oncology™ Hodgkin Lymphoma. V.2.2010. Available at http://www.nccn.org/professionals/physician_gls/PDF/hodgkins.pdf. Accessed November 2010.
  • Engert A, Eichenauer DA, Dreyling M; on behalf of the ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 suppl 4: iv108-iv109.
  • Younes A, Ong, T-C, Ribrag V, et al. Efficacy of panobinostat in Phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant.  Blood (ASH Annual Meeting Abstracts), 2009;114:923.
  • A Phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin's lymphoma. Available at http://www.clinicaltrials.gov/ct2/show/NCT01034163. Accessed November 2010.
  • Straus D. Relapsed and refractory Hodgkin lymphoma. Lymphoma Research Foundation. Available at http://www.lymphoma.org/atf/cf/%7B0363cdd6-51b5-427b-be48-e6af871acec9%7D/HL09RELREF.PDF. Accessed November 2010.
  • The Leukemia & Lymphoma Society. Hodgkin lymphoma facts & statistics. Availa
    '/>"/>

  • SOURCE Novartis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/2/2015)... Diversified Holdings (NYSE: CODI ) ("CODI," "we," ... market businesses, announced today its consolidated operating results for ... Fourth Quarter 2014 Highlights , Generated ... "Cash Flow") of $17.5 million for the fourth quarter ... 2014;  , Reported net income of $8.9 million ...
    (Date:3/2/2015)... Calif. , March 2, 2015  DURECT ... its Epigenomic Regulator Program, and the successful completion ... program,s lead product candidate DUR-928.  DUR-928 is an ... have broad applicability in metabolic diseases such as ... (NASH), and in acute organ injuries such as ...
    (Date:3/2/2015)... Click here for additional information on the earnings results . ... the nation,s largest independent specialty pharmacy, announced financial results for ... unless otherwise noted, are to the quarter or year ended ... include: , Revenue of $612 million, an increase ... increase of 11% , Gross margin of 6.7% versus ...
    Breaking Medicine Technology:Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 2Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 3Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 4Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 5Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 6Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 7Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 8Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 9Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 10Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 11Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 12Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 13Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 14Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 15DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 3Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 4Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 6Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 7Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 8Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 9Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 10Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 11Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 13Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 14Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 15Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 16Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 17Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 18
    ... Clot Retention and Decreases Residual Clot Volume , ... Cardiovascular LLC announced today that data presented at the ... Cardiothoracic Surgery show that administration of a heparin bolus ... vein harvest (EVH) was associated with improved acute saphenous ...
    ... , --First of 2 data sets to be released-- ... from two randomized, active-controlled clinical trials in patients with blepharospasm ... upper limb spasticity trial -- were presented at the Movement ... The studies were sponsored by Merz Pharmaceuticals, which plans to ...
    Cached Medicine Technology:Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients 2Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
    (Date:3/2/2015)... 02, 2015 Cutler Integrative Medicine a ... the root, gives cutting-edge tips to bring about self-renewal. ... renew the body by first cleaning house. According ... “We are all Toxic.” Between environmental toxins like heavy ... greatness, and our high stress levels, we all have ...
    (Date:3/2/2015)... Monroeville, PA (PRWEB) March 02, 2015 ... part of the Allegheny Health Network, are ... with new software called Visual Info Zonal Reminder (VIZR), ... , Introduced in 2013, Google Glass is a wearable ... in a smartphone-like hands-free format. Wearers communicate with the ...
    (Date:3/2/2015)... 2015 GBCHealth, a prominent business ... sector activities and investments in global health issues, ... new members to serve on the organization’s Board ... Chief Strategist and Co-founder of Partners In Health, ... Huma Abbasi, General Manager of Global Health and ...
    (Date:3/2/2015)... 02, 2015 Market Publishers Ltd is ... out by Global Industry Analysts Inc and recently added ... Research Report . Through 2018, the global radiation therapy ... The detailed research report suggests a holistic analysis of ... equipment as well as covers the top market trends. ...
    (Date:3/2/2015)... York, NY (PRWEB) March 02, 2015 ... Drug Administration (FDA) warned against the use of ... hysterectomies and fibroid removal surgeries, insurer UnitedHealthCare is ... the use of those devices. In a notification ... that beginning in April, it would require pre-authorization ...
    Breaking Medicine News(10 mins):Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4
    ... electronic, and patients, caregivers, and healthcare providers are ... health information. Now three institutions are teaming up ... best access this information. The Children,s ... based in Philadelphia, are partnering with Boston public ...
    ... for hepatitis C patients with end-stage liver disease are nearly ... to a Henry Ford Hospital study. Although infection ... the specific impact of the disease,s progressive severity on health ... severity of hepatitis C-related liver disease increases with age, and ...
    ... Scientists at Rochester Institute of Technology and Dowling College are ... cards, they are matching the protein to the job it ... drugs that target proteins and switch on or off specific ... funded by a $417,000 grant from the National Institutes of ...
    ... destroyed in type 1 diabetes Type 1 ... of sugar (glucose) in the blood. It is caused ... cells in their pancreas that produce the hormone insulin, ... about the mechanisms regulating the sensitivity and resistance of ...
    ... HealthDay Reporter , SUNDAY, Nov. 6 (HealthDay News) ... evoke the holiday season for some. For others, those ... noses and sneezing to asthma attacks. Allergists say ... have complaints from their patients about reactions to them. ...
    ... become fathers for the first time, they show significant decreases ... 19-year study. Researchers assessed more than 200 at-risk boys ... how men,s crime, tobacco, alcohol, and marijuana use changed over ... man,s negative behavior, they had not isolated the additional effects ...
    Cached Medicine News:Health News:Grant will help bridge digital divide for people with disabilities 2Health News:Grant will help bridge digital divide for people with disabilities 3Health News:The economic cost of advanced liver disease 2Health News:Opening the data bank -- scientists try to match new protein structures 2Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3Health News:Fatherhood can help change a man's bad habits 2
    CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
    ... Coagulation tubes contain a ... is available with a citrate ... or 0.129 mol/l (3.8%). The ... citrate solution to 9 parts ...
    Inquire...
    Inquire...
    Medicine Products: